Peptides Are Having a Moment — Here's What NPs Need to Know Right Now

 

NP CHRONICLES Clinical Awareness Brief

Peptides Are Having a Moment — Here's What NPs Need to Know Right Now

An FDA advisory panel is reconsidering compounding rules for BPC-157 and six other peptides, even as the basic science press stays deeply skeptical of the mail-order peptide trade.

If your patients haven't asked you about peptides yet, they probably will soon. This week the FDA convened a two-day advisory panel to reconsider whether compounding pharmacies should be allowed to prepare seven specific peptides — including BPC-157, a favorite of biohacking and "research use only" marketplaces — under prescription and physician oversight. The timing lands right on top of two other useful reads: a widely circulated science-blog takedown of the mail-order peptide trade, and a comprehensive academic review of legitimate, FDA-approved peptide therapeutics. Read together, the three pieces sketch out exactly where the clinical conversation with patients needs to go.

Two Very Different Worlds Called "Peptides"

Part of what makes this topic slippery in the exam room is that "peptide" means two different things depending on who is saying it. Chemically, a peptide is simply a short chain of amino acids — a category broad enough to include everything from digestive breakdown products to insulin itself. Clinically and commercially, "Peptides" (capital P, as science writer Derek Lowe puts it) has become shorthand for a specific class of injectable, mail-order compounds marketed for muscle building, fat loss, hair regrowth, tissue repair, and anti-aging — most of them sold with little to no human trial data behind them.

There are more than 80 FDA-approved peptide drugs on the market today, spanning diabetes care (the GLP-1 receptor agonists), oncology, cardiovascular disease, and antimicrobial therapy. Those drugs went through the same design-synthesis-modification-trial pipeline as any other pharmaceutical. The peptides driving patient questions in your clinic right now — BPC-157, various growth-hormone-releasing peptides, and others sold through gray-market suppliers — have not.

 

What's Actually on the Table at the FDA This Week

The panel isn't deciding whether to approve BPC-157 or its peers as drugs. It's deciding whether compounding pharmacies can legally prepare them under a prescription, for a specific diagnosis, with physician oversight — a narrower and more clinically supervised pathway than the current gray market, but still well short of full FDA approval with its accompanying efficacy and manufacturing standards.

●      BPC-157 is marketed for tissue and injury healing. As one physician noted in a recent STAT piece, it has been studied in roughly a dozen human subjects — compare that to the six-figure trial populations behind statins or GLP-1 drugs.

●      The Biden-era FDA had already added nearly 20 peptides to the list of substances compounding pharmacies should not prepare, citing insufficient safety data.

●      Most of the current advisory panel and agency staff involved in that 2020s-era decision are no longer in their roles, and HHS Secretary Robert F. Kennedy Jr. has publicly described himself as a supporter of these unapproved therapies.

●      The outcome will not constitute FDA approval of any of these peptides as drugs — it would only change who is legally allowed to compound them and under what supervision.

Why the Science Press Is Sounding the Alarm

Lowe's post (published on his long-running chemistry blog) walks through the mechanistic case for caution, and it's worth internalizing the framework even if you never mention his name to a patient:

●      Bioactivity is not the same as a known safety profile. Short peptides can have dramatic biological effects, but the field is still discovering off-target activity even for extremely well-studied hormones like insulin.

●      Reactivating growth pathways carries a generic cancer-risk concern. Growth hormone axis peptides in particular risk recreating the physiology of acromegaly — bone overgrowth, joint pain, hypertension, and type 2 diabetes — when taken outside physiologic feedback control.

●      Sourcing is a black box. Patients ordering from unregulated suppliers have no way to verify purity, concentration, or degradation, and no regulatory body compelling the supplier to care.

●      The appeal is often ideological as much as clinical — a "do my own research," anti-regulatory framing that can lead patients to discontinue well-evidenced therapies (statins, in the STAT anecdote) in favor of a compound studied in a literal handful of people.

AMBER FLAG — Don't Let the GLP-1 Comparison Do the Wrong Work Patients will sometimes reason, "GLP-1 drugs are peptides too, and those turned out great — so why not this one?" It's worth naming that logical leap directly. Semaglutide and liraglutide reached the market only after extensive sequence modification, half-life extension, and trial programs involving well over 100,000 patients combined. A gray-market peptide with a study population in the dozens has none of that behind it. Same molecular category, entirely different evidence base.

Case From Practice

"My Trainer Said BPC-157 Would Heal My Rotator Cuff Faster" A 34-year-old patient with a partial supraspinatus tear, already referred to physical therapy, asks whether you can prescribe or approve a BPC-157 regimen he found through an online fitness coach. He has done "his own research" and read that it's "basically a natural healing peptide." This is a good opening for motivational, non-adversarial patient education rather than a flat refusal-and-move-on. Points worth hitting: ●      Validate the goal (faster, better healing) before addressing the method — the desire to heal well is reasonable even if the chosen tool isn't. ●      Name the evidence gap plainly: BPC-157 has essentially no controlled human trial data for musculoskeletal healing, and no established dosing, purity standard, or long-term safety profile. ●      Ask where he'd be sourcing it — most patients haven't considered that an unregulated supplier has no incentive to guarantee what's actually in the vial. ●      Redirect to what does have evidence for tendon/rotator cuff recovery: structured PT progression, load management, and, where appropriate, evidence-based adjuncts you can actually document and monitor. ●      Document the conversation. If the patient proceeds through a gray-market source anyway, you want a clear record that risks were discussed.

Clinical Bottom Line

●      Legitimate, FDA-approved peptide drugs (GLP-1 receptor agonists, insulin analogues, GnRH-derived agents, ziconotide, etc.) are a mature, well-evidenced drug class — don't let "peptide" become a red-flag word in your own head. ●      Gray-market "research peptides" like BPC-157 are a separate category with minimal human data, unverified sourcing, and real theoretical risk (growth-pathway activation, cancer risk, contamination). ●      The FDA's current review is about compounding access under prescription, not drug approval — expect this to change the conversation with patients even if it doesn't change the evidence base. ●      Anticipate the question before the patient asks it. A brief, non-judgmental script ("tell me what you've read, here's what we actually know") keeps patients from sourcing these compounds entirely outside medical supervision.

Board Prep: Know Your Peptide Drug Classes

Certification exams love peptide pharmacology because it cuts across endocrine, cardiovascular, GI, and oncology content. A few high-yield associations worth drilling:

●      GLP-1 receptor agonists (exenatide, liraglutide, semaglutide, dulaglutide) — T2DM and weight management; GI side effects; class-wide caution in personal/family history of medullary thyroid carcinoma.

●      GnRH agonists/antagonists (leuprolide, degarelix) — hormone-responsive prostate cancer, endometriosis, precocious puberty; agonists cause an initial testosterone flare, antagonists do not.

●      Somatostatin analogues (octreotide) — acromegaly, carcinoid symptom control, variceal bleeding adjunct.

●      GLP-2 analogue (teduglutide) — short bowel syndrome; distinguish mechanism from GLP-1 on exam distractor questions.

●      N-type calcium channel blocker (ziconotide) — intrathecal use only for severe chronic pain; derived from cone snail venom, a good "where do peptide drugs come from" trivia point.

●      Natriuretic peptide analogue (nesiritide) — acutely decompensated heart failure; limited by hypotension risk and modest specificity.

References

Lowe, D. "Peptides. Where to Begin?" In the Pipeline (Science Translational Medicine blog), April 6, 2026.

Wang, L., Wang, N., Zhang, W., et al. "Therapeutic peptides: current applications and future directions." Signal Transduction and Targeted Therapy 7, 48 (2022). https://doi.org/10.1038/s41392-022-00904-4

Breen, K., Yamaguchi, A. "FDA panel reviewing some peptides to consider loosening regulations for unapproved therapies." CBS News, July 23, 2026.

NP Chronicles — Clinical education for NP students and new graduates since 2012.